HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by O’Connor, C. M. Search for Related Content PubMed PubMed Citation Articles by O’Connor, C. M.

Tezosentan in patients with acuteheart failure and acute coronary syndromes

Results of the randomized intravenous tezosentan study (ritz-4)

Christopher M. O’Connor, MD, FACC^*, Wendy A. Gattis, PharmD^*,*, Kirkwood F. Adams, Jr, MD, FACC, Vic Hasselblad, PhD^*, Bleakley Chandler, MD, FACC, Aline Frey, PharmD, Isaac Kobrin, MD, Maurizio Rainisio, PhD, Monica R. Shah, MD^*, John Teerlink, MD, FACC^||, Mihai Gheorghiade, MD, FACC^¶ RITZ-4 Investigators

^* Duke University Medical Center and Duke Clinical Research Institute, Durham, North Carolina, USA
University of North Carolina, Chapel Hill, North Carolina, USA
University Hospital of Augusta, Augusta, Georgia, USA
Actelion Ltd., Basel, Switzerland
^|| University of California in San Francisco, San Francisco, California, USA
^¶ Northwestern University, Chicago, Illinois, USA

View larger version (13K): [in a new window]   Figure 1 Kaplan-Meier plot of the composite primary end point: death, worsening heart failure, recurrent ischemia, and recurrent or new myocardial infarction within 72 h.